A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC) - None

Study identifier:D5082C00002

ClinicalTrials.gov identifier:NCT02127710

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC)

Medical condition

Papillary Renal Cell Cancer

Phase

Phase 2

Healthy volunteers

Study drug

AZD6094

Sex

All

Actual Enrollment

111

Study type

Interventional

Age

18 Years - 99 Years

Date

Study Start Date: 30 Apr 2014

Primary Completion Date: 14 Apr 2016

Study Completion Date: 20 Apr 2020

Study design

Allocation: N/A
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2021 by AstraZeneca

Collaborators

SCRI Development Innovations, LLC

Inclusion and exclusion criteria

Inclusion Criteria

1) Provision of informed consent prior to any study specific procedures, sampling and analyses.
2) Histologically confirmed PRCC, which is locally advanced or metastatic.
3) Availability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by a central laboratory and other biomarker
4) Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.
5) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6) At least one lesion, not previously irradiated, and not chosen for a biopsy if performed during the screening period that can be accurately measured at baseline and which is suitable for accurate repeated measurements.
7) Adequate hematological function defined as:
a. Absolute neutrophil count ≥1500/μL
b. Haemoglobin ≥9 g/dL
c. Platelets ≥100,000/μL
8) Adequate liver function defined as:
a. Alanine aminotransferase and aspartate aminotransferase ≤2.5 x the upper limit of normal (ULN)
b. Total bilirubin ≤1.5 x ULN
9) Adequate renal function defined as glomerular filtration rate ≥ 40 mL/min,
10) Adequate coagulation parameters, defined as International Normalisation Ratio <1.5 x ULN or activated partial thromboplastin time <1.5 x ULN.
11) Patients with known tumor thrombus or deep vein thrombosis are eligible if stable on low molecular weight heparin for ≥4 weeks.
12) Females should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential
13) Male patients should be willing to use barrier contraception, i.e. condoms.
14) Ability to swallow and retain oral medications.
15) Predicted life expectancy ≥12 weeks.
16) Aged at least 18 years.
17) Willingness and ability to comply with study and follow-up procedures.
18) Ability to understand the nature of this study and give written informed consent.

Exclusion Criteria

1) Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents <21 days of the first dose of study treatment. Most recent targeted therapy <14 days of the first dose of study treatment.
2) Unresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events Grade 1 at the time of starting study treatment with the exception of alopecia.
3) Prior or current treatment with a cMet inhibitor
4) Strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), strong inhibitors of cytochrome P450 1A2 (CYP1A2), or CYP3A4 substrates with a narrow therapeutic range within 2
weeks before the first dose of study treatment (3 weeks for St John’s Wort)
5) Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy
6) Major surgical procedures ≤28 days of beginning study drug or minor surgical procedures ≤7 days. No waiting is required following port-a-cath placement.
7) Previously untreated brain metastases.
8) Current leptomeningeal metastases or spinal cord compression due to disease.
9) Acute or chronic liver or pancreatic disease.
10) Uncontrolled diabetes mellitus.
11) Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy
12) Any of the following cardiac diseases currently or within the last 6 months:
a. Unstable angina pectoris
b. Congestive heart failure (New York Heart Association ≥ Grade 2)
c. Acute myocardial infarction
d. Stroke or transient ischemic attack
13) Inadequately controlled hypertension (i.e., systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) (patients with values above these levels must have their blood pressure controlled with medication prior to starting treatment).
14) Mean resting correct QT interval (QTc) >470 msec obtained from triplicate electrocardiagrams
15) Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec.
16) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family history of unexplained sudden death under 40 years of age or any concomitant medications known to prolong QT interval.
17) Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.
18) Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
19) Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
20) Presence of other active cancers, or history of treatment for invasive cancer ≤5years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
21) Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled. This group is considered sufficient to provide preliminary assessment of the anti-tumour activity of AZD6094 in the form of non-binding futility analysis. If ≤ 2 tumour responses are observed in the first 20 evaluable patients termination of the study will be considered taking into account the relevant molecular profile of the patients and additional information from related studies in the drug development programme. All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously. Following the baseline assessment, efficacy will be assessed by objective tumour assessments every 6 weeks (±7 days), for the first 12 months and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1 There will be a data cut-off after all patients have completed at least 12 weeks of treatment with AZD6094 or withdrawn. The database will be locked and data analysis will be performed on this dataset. Any patients still receiving study drug at the time of data cut-off will be able to continue to receive AZD6094 while deriving clinical benefit. Such patients will continue to be monitored for the occurrence of serious adverse events up to 28 days after the last dose of AZD6094. After database lock (DBL) tumour assessments will be performed every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1. Patients discontinuing treatment due to documented disease progression will enter a survival follow-up period, where they will be followed for the initiation of subsequent anti-cancer therapies every 3 months until death, loss to follow-up or withdrawal of consent, whichever comes first. Patients discontinuing treatment prior to documented disease progression will enter a progression-free survival follow-up period where they will continue to have disease assessments every 6 weeks (±7 days) for the first 12 months of follow-up and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1, death, loss to follow-up or withdrawal of consent, whichever comes first. After DBL, tumour assessments will be performed in the progression free survival patient population every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1

No locations available

Arms	Assigned Interventions
Experimental: AZD6094 600 mg daily continuously All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.	Drug: AZD6094 AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor. Other Name: Savolitinib Other Name: HMPL - 504

Documents available

D5082c00002-revised-csp-3_Redacted
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Contact Backup

Cancer Study Locator

877 400 4655